AkebiaCares

Your trusted partner in coverage solutions

They are extremely easy to work with. I am very thankful for having that support for my patients and them always being available.”

— Constance Nicastro-Bowman, CNP Nurse Practitioner

Coverage solutions
made simple

MEDICARE LIS/DUAL ELIGIBLE

  • AURYXIA is on formulary at all major Medicare Part D Plans1
    • Prior authorization required to confirm diagnosis
  • All Medicare full Low-Income Subsidy (LIS)/dual-eligible patients can pay no more than $10.00 per fill of AURYXIA

COMMERCIAL INSURANCE

  • AURYXIA is on formulary with the majority of commercial plans2
    • With the AURYXIA Copay Coupon, eligible patients can pay as little as $0 per fill*

UNINSURED/MEDICARE PART D

  • FREE AURYXIA may be provided to eligible patients†:
    • Who don’t have insurance
    • Who have Medicare Part D insurance but cannot afford their copays
    • Whose insurance does not cover AURYXIA

Download enrollment form

case manager

Prior authorizations claims are resolved in a timely manner

AkebiaCares provides eligible patients with coverage support and medicines at no cost

REIMBURSEMENT HELP

REIMBURSEMENT HELP

One-on-one support for assistance with insurance questions and challenges

PATIENT ASSISTANCE PROGRAMS (PAP)

PATIENT ASSISTANCE PROGRAMS (PAP)

Free AURYXIA may be available for eligible patients with Medicare Part D insurance‡

  • For patients who are uninsured or have other coverage concerns, AkebiaCares offers comprehensive patient services that may be able to help
COPAY COUPON

COPAY COUPON

Financial assistance for patients with commercial insurance§

  • Download the Copay Coupon at AkebiaCares.com or pick it up at pharmacies nationwide

VIEW COPAY COUPON

Find pharmacies that dispense AURYXIA

Search by ZIP code to locate an AURYXIA network specialty pharmacy.

Get started

Download Pharmacy Locator Flashcard

*Restrictions may apply. Copay assistance is not valid for prescriptions reimbursed under Medicare, Medicaid, or similar federal or state programs.
†Patients with an income of up to 400% Federal Poverty Level (FPL) may be eligible for free AURYXIA. Additional restrictions apply.
AkebiaCares does not guarantee coverage and/or reimbursement for all patients.
‡Medicare Part D patients with an annual income of ≤150% of the Federal Poverty Level are eligible for LIS assistance (also called “Extra Help”).
§Copay assistance is not valid for prescriptions reimbursed under Medicare, Medicaid, or similar federal or state programs.
CKD=chronic kidney disease.

IMPORTANT SAFETY INFORMATION AND INDICATION

CONTRAINDICATION

AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis

WARNINGS AND PRECAUTIONS

  • Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores. Assess iron parameters prior to initiating AURYXIA and monitor while on therapy. Patients receiving concomitant intravenous (IV) iron may require a reduction in dose or discontinuation of IV iron therapy
  • Risk of Overdosage in Children Due to Accidental Ingestion: Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Advise patients of the risks to children and to keep AURYXIA out of the reach of children

ADVERSE REACTIONS
The most common adverse reactions reported with AURYXIA in clinical trials were:

  • Hyperphosphatemia in CKD on Dialysis: Diarrhea (21%), discolored feces (19%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%)

SPECIFIC POPULATIONS

  • Pregnancy and Lactation: There are no available data on AURYXIA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation. Data from rat studies have shown the transfer of iron into milk, hence, there is a possibility of infant exposure when AURYXIA is administered to a nursing woman

INDICATION

AURYXIA® (ferric citrate) is indicated for:

  • The control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis

To report suspected adverse reactions, contact Akebia Therapeutics, Inc. at 1-844-445-3799

Please see full Prescribing Information

REFERENCES

  1. Data on File 29, Akebia Therapeutics, Inc.
  2. Data on File 30, Akebia Therapeutics, Inc.